Lee Eppstein
Direttore Tecnico/Scientifico/R&S presso New Brunswick Scientific Co., Inc.
Profilo
Lee Eppstein has worked as a Director at Antyra, Inc. and as a Vice President-Technology at New Brunswick Scientific Co., Inc.
Posizioni attive di Lee Eppstein
| Società | Posizione | Inizio |
|---|---|---|
New Brunswick Scientific Co., Inc.
 New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Direttore Tecnico/Scientifico/R&S | 01/02/2000 |
Antyra, Inc.
 Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
New Brunswick Scientific Co., Inc.
New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |
- Borsa valori
- Insiders
- Lee Eppstein
